Biogen beats estimates on multiple sclerosis therapy sales

Drugmaker Biogen Inc beat analysts' estimates for quarterly profit and lifted its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis therapy Tecfidera.